Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

Peritoneal Cancer ◽

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.05.028 ◽

2012 ◽

Vol 126 (3) ◽

pp. 369-374 ◽

Cited By ~ 23

Author(s):

Marcela G. del Carmen ◽

John Micha ◽

Laurie Small ◽

Daron G. Street ◽

Anil Londhe ◽

...

Keyword(s):

Clinical Trial ◽

Fallopian Tube ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Clinical Trial ◽

Peritoneal Cancer ◽

Platinum Sensitive

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5571 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5571-5571 ◽

Cited By ~ 5

Author(s):

Iurie Bulat ◽

Kathleen N. Moore ◽

Alexei Haceatrean ◽

John Woojune Chung ◽

Prabhu Rajagopalan ◽

...

Keyword(s):

Fallopian Tube ◽

Liposomal Doxorubicin ◽

Antibody Drug Conjugate ◽

Phase Ib ◽

Peritoneal Cancer ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2006.00298.x ◽

2006 ◽

Vol 16 (1) ◽

pp. 65-70 ◽

Cited By ~ 22

Author(s):

M. VERHAAR-LANGEREIS ◽

A. KARAKUS ◽

M. van EIJKEREN ◽

E. VOEST ◽

E. WITTEVEEN

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

10.1136/ijgc-2020-igcs.322 ◽

2020 ◽

Author(s):

A Santin ◽

I Vergote ◽

A Martín ◽

K Moore ◽

A Oaknin ◽

...

Keyword(s):

Fallopian Tube ◽

Liposomal Doxorubicin ◽

Antibody Drug Conjugate ◽

Peritoneal Cancer ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-0158 ◽

2021 ◽

pp. clincanres.0158.2021

Author(s):

Kathleen N. Moore ◽

Setsuko K. Chambers ◽

Erika P. Hamilton ◽

Lee-may Chen ◽

Amit M. Oza ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Peritoneal Cancer ◽

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5585 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5585-5585 ◽

Cited By ~ 2

Author(s):

Kristen Paige Bunch ◽

Anne M. Noonan ◽

Jung-min Lee ◽

Ciara Catherine Maria O'Sullivan ◽

Nicole D. Houston ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Pharmacodynamic Biomarkers

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyv016 ◽

2015 ◽

Vol 45 (5) ◽

pp. 422-426 ◽

Cited By ~ 6

Author(s):

T. Nakanishi ◽

D. Aoki ◽

Y. Watanabe ◽

Y. Ando ◽

N. Tomotsugu ◽

...

Keyword(s):

Clinical Trial ◽

Fallopian Tube ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Japanese Patients ◽

Phase Ii Clinical Trial ◽

Peritoneal Cancer ◽

Platinum Sensitive

Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5608 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5608-TPS5608 ◽

Cited By ~ 1

Author(s):

Kathleen N. Moore ◽

D. Scott McMeekin ◽

Erika Paige Hamilton ◽

Donald K Strickland ◽

Suzanne Fields Jones ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Randomized Phase Ii